Bristol-Myers (BMY) Earnings Call Transcript
View original at nasdaq.comBristol-Myers (BMY) Earnings Call Transcript Image source: The Motley Fool. Date Oct. 30, 2025 at 4:06 p.m…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Reblozyl annualizing over $2B in revenue
80% confidenceOperating expenses expected at ~$16.5B in 2025, representing over $1B net savings versus 2024
80% confidenceADEPT-2 study data for Cobenfy in Alzheimer's disease psychosis expected end of 2025
80% confidenceSotyktu direct-to-patient program offers >80% discount effective January 1
80% confidenceAnti-tau antibody Phase II data expected in 2027
80% confidenceBreyanzi annualizing over $1B in revenue
80% confidenceAll 3 milvexian Phase III trials (AFib, ACS, SSP) now expected to read out in 2026
80% confidenceUS manufacturing hub opened for radiopharmaceutical therapies with 3-day delivery to patients
80% confidencePumitamig early data to be presented at San Antonio Breast Cancer Symposium in December 2025
80% confidenceSotyktu pivotal studies for autism spectrum irritability to initiate in 2026
80% confidenceCamzyos annualizing over $1B in revenue
80% confidenceDiscussions with FDA and multiple regulators for accelerated/conditional approval of iberdomide
80% confidenceNon-GAAP EPS guidance for 2025: $6.40-$6.60 with midpoint unchanged but range narrowed
80% confidenceMilvexian targeting approximately 40% of AFib patients unsuitable for Factor Xa anticoagulants
80% confidenceDiscussions with administration on Medicare/Medicaid pricing are frequent and constructive
80% confidenceBy end of decade, potential for 10 new medicines and ≥30 life cycle management opportunities
80% confidenceStrategic productivity initiative targeting $2B savings by 2027 with clear line of sight confirmed
80% confidenceFull-year 2025 revenue guidance raised to $47.5B-$48B, representing $750M increase at midpoint
80% confidenceCobenfy has achieved virtually 100% access in Medicare/Medicaid in US
80% confidenceNo plan to revisit Eliquis IRA negotiation, price effective January 1, 2026
80% confidenceEliquis direct-to-patient program offers >40% less than list price
80% confidenceLegacy portfolio expected to decline 15%-17% in 2025
80% confidenceCobenfy achieving over 2,400 weekly TRxs
80% confidenceDebt paydown target of $10B by first half 2026, with $6.7B already repaid
80% confidence2 additional Cobenfy Alzheimer's disease psychosis studies expected in 2026, need 2 of 3 positive for approval
80% confidenceIberdomide PFS data expected in 2026
80% confidenceNext 12-24 months will see data for 7 new molecular entities and 7 life cycle management opportunities
80% confidenceOpdivo + Qvantig expected to achieve high single-digit to low double-digit growth full year (raised guidance)
80% confidence